# OPK earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/OPK) · [Earnings tab](https://www.lopjlb.com/stock/OPK?tab=earnings)

Updated: 2026-07-27T04:16:47

Quarters analyzed: 8

## Cross-quarter narrative

Across the series of OPKO Health CallCards, the company moved from a cash‑burning, revenue‑declining position in early 2024 toward a more disciplined, cash‑flow‑positive outlook by early 2026. Early calls highlighted a weakened margin environment, heavy reliance on Pfizer manufacturing, and a looming FTC review that threatened the Labcorp divestiture and cash‑flow breakeven timeline. By Q2 2024 the firm secured a $250 million royalty financing, narrowed diagnostic losses and announced a $100 million buy‑back, while the Labcorp transaction remained on track. Subsequent quarters emphasized accelerated ModeX program activity, multiple Phase‑1 initiations, expanded BARDA funding and a completed BioReference oncology sale in Q3 2025, which together improved margins and reduced operating loss. Throughout, the company maintained a focus on non‑dilutive funding, cost‑reduction programs and share repurchases. However, regulatory timing, clinical development milestones and foreign‑currency headwinds persisted as recurring concerns, while early partner‑dependence and competition fears faded as the Pfizer issue cleared and the Moderna EBV vaccine competitor was no longer cited. The narrative reflects a transition from uncertainty and cash strain to a clearer path toward profitability anchored by diversified pipelines and strategic divestitures.

## Latest CallCard · Q4

OPKO Health exited 2025 with momentum after BioReference oncology divestiture, advancing ModeX pipeline with 3 clinical programs, Regeneron collaboration worth >$1B milestones, BARDA funding, and $109M share repurchases; guiding 2026 revenue $530-560M with BioReference profitability target.','tone':

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2025 Q4:** OPKO Health exited 2025 with momentum after BioReference oncology divestiture, advancing ModeX pipeline with 3 clinical programs, Regeneron collaboration worth >$1B milestones, BARDA funding, and $109M share repurchases; guiding 2026 revenue $530-560M with BioReference profitability target.','tone':
- **2025 Q3:** OPKO Health reports Q3 2025 results, completed the BioReference oncology divestiture, strong cash position, advancing multiple therapeutics and diagnostics, and provides Q4 and 2026 guidance expecting diagnostic profitability and modest pharma growth.
- **2025 Q2:** OPKO Health advances BioReference oncology sale to Labcorp (closing near end Q3), ModeX pipeline progress with 5 INDs planned, OPK-88006 GLP-1/glucagon dual agonist shows preclinical superiority, BARDA funding expands, share repurchase ongoing, 2025 guidance maintained with cash flow breakeven targe
- **2025 Q1:** OPKO sold BioReference oncology to Labcorp for up to $225M, targets BioReference profitability in 2025, advances GLP-1/glucagon programs (subcu and oral) and ModeX pipeline, guides FY25 revenue $675-685M. Net loss $67.6M, cash $450M. Share repurchase expanded to $200M, convertible debt exchange comp
- **2024 Q4:** OPKO reports transformative 2024 with multiple Phase 1 launches, BARDA funding, and a path to Q1 2025 profitability, while relying on partner milestones and regulatory timelines.
- **2024 Q3:** —
- **2024 Q2:** OPKO Health Q2 2024: $250M royalty financing, Labcorp deal closing Sep/Oct, ModeX pipeline advancing (MDX2001 Phase 1 dosing soon, EBV vaccine with Merck), BioReference narrowing losses, $100M buyback authorized.
- **2024 Q1:** OPKO Health reports Q1 2024 revenue decline, advances NGENLA launch and ModeX pipeline, and targets cash‑flow breakeven mid‑year pending LabCorp divestiture.

## Theme arcs

- **Revenue trajectory** (improving): Q1 2024 revenue decline gave way to guidance of FY25 revenue $675‑685 M and Q4 2025 profitability expectations.
- **Cash management** (improving): Initial operating loss of $71.5 M shifted to cash‑flow breakeven targets and strong cash balance $450 M by FY25.
- **Regulatory environment** (stable): FTC antitrust risk noted early, later replaced by IND filing timing risk that remains ongoing.
- **Partner dependence** (resolved): Pfizer manufacturing reliance cited in Q1 2024 but not mentioned in later calls.
- **Competitive landscape** (resolved): Moderna EBV vaccine competition flagged in Q1 2024, absent thereafter.
- **Funding continuity** (deteriorating): BARDA funding highlighted as critical, with uncertainty about future commitments.
- **Currency impact** (deteriorating): Strong dollar headwinds noted in Q4 2025 and Q3 2025 affecting pharma margins.

## Fear persistence

- **Regulatory risk** [recurring]: FTC antitrust review early, later IND filing timing risk persists.
- **Funding continuity risk** [recurring]: BARDA funding critical; future commitments uncertain.
- **Clinical development risk** [recurring]: ModeX trial timelines and data generation remain uncertain.
- **Commercial adoption risk** [recurring]: Success of NGENLA, 4Kscore and other launches depends on market uptake.
- **Currency risk** [recurring]: Strong dollar impacts pharma revenue and margins.
- **Partner dependence** [resolved]: Pfizer manufacturing reliance cited only in Q1 2024.
- **Competitive risk** [resolved]: Moderna EBV vaccine competition mentioned only in Q1 2024.
- **Cash burn risk** [resolved]: Operating loss highlighted in Q1 2024, later mitigated by cash‑flow breakeven targets.

## Guidance path

2024 Q1:lowered → 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/OPK`